Melanoma Clinical Trials

Showing 941-960 of 1,477 trials

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

NCT01826448

The purpose of this research study is to test the safety of an investigational new drug called PLX3397 when used in combination with Vemurafenib (Zelboraf™) at different dose levels. Vemurafenib has been approved by the United States Food and Drug Administration (FDA)/European Medicines Agency (EMA) for the treatment of a specific category of unresectable or metastatic melanoma.

V600-mutated BRAF Unresectable MelanomaV600-mutated BRAF Metastatic MelanomaStage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

Daiichi Sankyo13 participantsStarted Nov 2013

Los Angeles, California, United States • Aurora, Colorado, United States • Nashville, Tennessee, United States +3 more locations

TERMINATEDPhase 1

Safety of ADU-1604 in Adults With Metastatic Melanoma

NCT03674502

This study is a first-in-human, open-label, multicenter, dose-escalation study designed to evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults with metastatic melanoma.

Metastatic Melanoma

Aduro Biotech, Inc.4 participantsStarted Nov 2018

Marseille, France • Paris, France • Villejuif, France +2 more locations

TERMINATEDPhase 1

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03565406

This is a Phase 1b, open-label, dose-escalation cohort study. The study will consist of a dose escalation assessment of the safety and tolerability of Mocetinostat administered concurrently in combination with ipilimumab and nivolumab to patients with advanced melanoma. Treatment will be divided into induction and maintenance phases. It is anticipated that this clinical study will enable selection of the RP2D and dose schedule of this 3-drug combination for further clinical testing. The trial will include an assessment of the pharmacodynamic activity of Mocetinostat administered in combination with ipilimumab and nivolumab.

Melanoma

NYU Langone Health11 participantsStarted Apr 2018

New York, New York, United States

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

Safety of ADU-1604 in Adults With Metastatic Melanoma

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Related Searches

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Spanish Registry of Mohs Surgery

Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma

Health Communication in Families

Flavopiridol in Treating Patients With Metastatic Malignant Melanoma

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Suicide Plus Immune Gene Therapy for Advanced Melanoma

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma